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Objectives. Thii study was designed ti- examine the variation in 
mortnlltt mtesamnng cuttries participating in the International 
Tiiue Flastttinogen ActivatorlStreptokinlw Mortality Trial. 
Bac&wnd. Despite uniform inciusion and exclusion criteria 
and prot& in this trio& %-day mortality rates (irrespective of
IroshnenI oltocotkm) ranged from 4.2% to 14.8% antong the 
porticipathIgcoontries. 
8fethods. With use or the risk doctors identified by o multi- 
wrlnte IcgIstic m~&l, the total study group was classified into 
de&s on the hasis of eacit patient’s risk profile asd I;d.vidual 
prohobitity of dying within Xl days. Expsted mortality rutes were 
then eulculrted and compared with aetttal mortality for each 
decile of the total study group, as well as for patients from each 
country. 
Rrsnftr. Independent risk factors for mortality were older age 
(odd5 ratio 1.91 for each lO.yenr increment), systolic hypoteosion 
Nml ptssuro <95 mm Ii@ at entry (odds ratio 3.7). Killip class 
>l at entry (odds ratio 3.5). history of ante&&eat angina (odds 
ratio 1.w to 1.491, history of diaketes meIlitus (odds ratio I.&IL 
Thirteen countries participated in the International Tissue- 
Type Plasminogen Activator (r&PA) and Streptokinase Mor- 
tality Trial (2.3). The same treatment protocol with uniform 
inclusion and exclusion criteria was used in all countries. 
The purpose of the trial wry to compare the safety and 
efficacy OF t-t-PA versus strep;okinase with and withaul 
heparin in reducing in-hospital as well as 6-month mortality. 
No significant differences in mortality were observed be- 
tween the ri-PA and streptokinase treatment arms (2.31. 
This report describes an analysis of the tolal 30&y 
morlality rates (irrespective of treatment arm) observed 
among the I3 countries that participated in the lrial. Despite 
identical inclusion criteria and trea:ment protocol. the over- 
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previous infaretimt (edds ratio 1.23) und history of never smokiq 
(odds ratio 1.37). 
The overall mortality rate omoop tke 1,612 ps(irati in ri.& 
dffiles 9 and 10 WBS 26%; for the 1,686 p&o& in de&s 1 L& 
2 it war I.2%, with a wrisititity of 41.6% 
83.7%. The tog&tie model closly 
ditierrnt mortali@ rates for most 
tween expefted and actual lno&li 
ever. in the total siody group;& difference betwan tke enpctcd 
and actual mortality war sign&ant (p < O.QDl). Third&T- 
was mninly OX&Ed to the two cunntries wltll the ugkest and 
lowest mortality rates. When the patiaksfm tkse h90 IXW&S 
were excluded from the aualysis, the ore&l diiereoce beeume 
nonsigniFicant. 
ConcfUsions. These sildiog suggest that the reeognw risk 
t’acto~s aaoeiated with imxesed case fatality io acute q yowdial 
infarction acmuot ooIy in part for mortzdity di&rences wes or 
within popdatttm. 
(_I Am ColJ Cordicd 1993;21881-6) 
all 30-day mortality among countries ranged from 4.2% to 
14.8%. A multivariate logistic model based on information 
collected during the hospital stay and early after discharge 
was used to evaluate factors possibly associated with in- 
creased mortality. 
Methods 
Study group. From October 1988 to August 1989, 8.387 
cGnserutive patients with acute evolving myocardial infarc- 
tion were randomized lo receive either &PA or streptoki- 
nase with or wilhout subcutaneous heptin. Hence, there 
were four treatments in this open trial-streptokinase alone, 
streptokinase plus heparin. rt-PA alone and rt-PA plus 
heparin. The study design, the trial medications and the 
recommended treatme:.tc have been described in detail 
elsewhere (2.3). In brief, patients admitted to the patticipat- 
ing coronary care units were eliiible for cenlti randomiza- 
tion I) if they had chest pain accompanied by ST segment 
elevation of 21 mm in any limb lead of the electrocardio- 
gram (EC@ or of 22 mm in any precordic! tend: 2) if 
thrombolytic infusion could be initiated within 6 h from the 
onset of symptoms; and 3) if they had no clear contraindi- 
cation to the fibrinolytic treatment or to heparin. No age 
restriction was imposed. The purpose of the analysis was not 
to identify the countries with the best or worst mortality 
rates, but to explore whether recognized risk factors can 
account for differences in mortality in different populations. 
For this reason, participating countries are noted by number 
in order of study group size (1 = largest group) rather than 
by name. 
Stndy protoal and statistical analyses. Patients were fol- 
lowed up for 6 months after admission. Data on rehospital- 
ization, reinfarction. invasive procedures and mortality were 
available on all but 245 patients (2.9%). In addition, institu- 
tional information-specifically, number of beds, university 
atfiliation and presence of both cardiac catheterization or 
cardiovascolar surgical service+was obtained for each 
center. 
Quality assurance of the data was performed by clinical 
trial monitors both at the national coordinating centers in 
each country and at the inte~ational coordinating center in 
Leuven, Belgium. The case report forms were carefully 
reviewed and anomalies or queries about the data were then 
referred to the participating center for clarification and 
foliowed up by the clinical trial monitors. 
Univariate age-adjusted mortality rates for each baseline 
variable were calculated by the direct method and compared 
by normal approximation for proportions (4). 
The icdependent effect of baseline palient and institu- 
tional characteristics was evaluated in the total study group 
by mtdtiple logistic regression (Biomedical Computer Pro- 
gram University of California [BMDPI program LR). Seven 
baseline characteristics independently associated with in- 
creased 30.day mortality were identified, and the indepctt- 
dent probability of death associated with each of them was 
assessed. 
Using the risk factors identified by the logistic model, the 
probability of dying was calculated for each patient on the 
basis of his or her risk profile. The total study group was 
classified into deciles on the basis of each patient’s proba- 
bility of dying. On the basis of these probabilities, expected 
mortality rates were calculated and compared with actual 
mortality for each decile of the total study group, as well as 
for each country. The overall significance of the differences 
between the observed and expected mortality rates among 
deciles and countries was examined by the Hosmer- 
Lemeshow test (5). 
To identify the countries that contributed to the overall 
difference between the observed and the expected mortality 
rate, this test was repeated excluding countries from analy- 
sis, one by one, starting with those with the largest observed 
lo expected discrepancy, until the overall difference became 
nonsignificant. This analysis included 8.043 of the 8,387 
patients enrolled in the trial. Patients enrolled in oae country 
(country 13) were excluded because of the small size of the 
group (n = 37). Three hundred seven additional patients 
(3.7%) for whom not all baseline variabl?s were available 
were also excluded from this analysis. The proportion of 
patients with missing baseline or follow-up data did not differ 
significantly among the countries. 
In addition, mortality odds ratios associated with each of 
the seven risk factors were assessed separately in each 
country. The homogeneity of these country-specitic odds 
ratios was examined for each risk factor by a test for 
interaction (4). 
Patient characteristics and clinical coourse (Tables 1 and 2). 
A total of 8,387 oatients were enrolled in the trial. Analvsis 
included 6,142 men aged 61 + II years and 1,901 women 
aged 67 f IO years (p < 0.0001). Despite similzr entry 
criteria, the baseline characteristics varied among countries 
(Table I). The mean age ranged from 56 to 66 years; the 
proportion of men ranged from 73.2% to 85.0%; the preva- 
lence of diabetes mellitus ranged from 5.6% to 19.5% and 
that of previous infarction from 14.2% to 23.8%. of anteced- 
ent angina from 33.3% to 59.2% and of hypertension from 
21.3% to 48.71, the proportion of patients who never 
smoked ranged from 11.1% to 36.0% and that of patients 
with a Killip class >I ranged from lO.G% to 28.3%. 
Hospital clinical comse for the patients in each country is 
summarized in Table 2. Clinical reinfarction was reported in 
0.6% to 5.5% of the patients, and 4.3% to 13.5% of the 
patients had at least one episode of ventricular fibrillation. 
Stroke occurred in 0.8% to 2.7% of the patients and bleeding 
complications were reported in 2.7% to 8.%. Mean length 
of stay ranged from 8 ? 5 days to I4 f 9 days. The rate of 
in-hospital revascularization procedures was relatively low 
in all participating countries and ranged from 0.0% to 6.2% 
for coronary angioplasty and from 0.0% to 4.3% for coronary 
bypass surgery. Country 5 had a considerably higher rate of 
coronary bypass surgery (4.3% vs. 0.0% to 1.8% in a8 other 
counlries [p < O.OWJIlk The rate of coronary angioplasty 
was the highest in country 2 (6.2% vs. 0.6% to 3.4% in all 
other countries [p < O.ooOl]). However, in both country 5 
and country 2 mortality was evenly distributed among pa- 
tients who did and did not undergo invasive coronary 
pmcedures. 
Analysts nf mortality r&s by eottntry and sssociatcd risk 
factors (Tables 3 lo 5). Table 3 lists the in-hospital and 
30-day mortality of patients enrolled in each country. The 
highest 38day mortality rate was observed in country 5 
(14.8%) and the lowest tale in country I2 (4.2%). The 
respective in-hospital mortality rates were 13.3% and 4.2%. 
hiuhivariate analysis accounting for all baseline variables 
performed on the total study group identitied the following 
seven independent risk factors associated with increased 
30-day mortality: age. antecedent angina pectoris, history of 
diabetes mellitus, history of previous infarction, history of 
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Table 3. Hospital and 3May Mortality by Counl~-~ 
Cumulative 
Hospital 3Mky 
hlicllts 
Mortality Monality 
~ - 
Cwntry EN&d NO. % NO. 96 
1 1,526 IZI 7.9 112 8.6 
2 1.092 61 5.6 68 6.2 
3 I,(11 w 9.1 102 9.7 
: 1,019 723 93 6 13.3 9.t IO1 D7 14.8 9.9 
6 SW 40 7.3 44 8.0 
7 526 45 8.6 47 9.0 
8 525 61 II.6 64 12.6 
9 4B9 42 8.6 47 9.6 
IO 186 23 6.0 26 6.8 
II 344 34 9.9 33 10.2 
12 120 5 4.2 
13 37 5 13.5 
: 4.2 
13.5 
Tnal 8,387 124 8.6 185 9.4 
never smoking, Killip class Z-1 and systolic hypotension 
(blood pressure ~95 mm Hg) at admission. 
Table 4 lists the age-adjusted mor?ality rates and Table 5 
presents the independent odds ratios for each of these 
baseline characteristics that were associated with increased 
T&k 4. Age.Adjusied Z-Day Mortality Rates (%) by 
Baseline Characteristics Independently Ass&&d With 
Mortality (n = 8013)’ 
Crude 
Total lta~c tpcr l.MMI r.valuet 
6,142 7,l B.4 
1,901 12.8 IQ.3 <4,001 
kvious infarction 
Yes 1,565 13.9 12.7 
NO 
Antecedent agina 
Yes 
ii0 
B”IOkinB 
Never smoked 
Active and ea.smokers 
Diabcks meltitus 
YCS 
ND 
SyrIatic BP 11 entry 
595 mm Hg 
>9s mln HB 
Killip class * entry 
class St 
Class 2-J 
b,47B 
3.743 
4,3M) 
2,318 
5.725 
a3 
7,140 
519 
7,SR 
6S62 
1,328 
7.7 8.0 
II.5 11.0 
6.6 7.1 
13.5 10.9 
7.0 7.9 
14.7 14.1 
8.2 8.2 
26.8 25.9 
7.7 7.7 
5.6 b.0 
19.4 16.9 
CO.tWl 
<0.11001 
at&u 
<O.(lwl 
<O.ooOl 
<O.WOlf 
uasr=4 I53 58.2 $6.3 
‘Excluding counlry 13 because of small study p~pulalion and 301 patients 
fmmclbereountdrswitb incomplete baselincvariabks.tCamparingadjdsted 
rates of 3Dday motiity. ?&mpariming adjusted rites of Kalip class = I VI. . __ . 
3Oday mortality: age, history of previous myocardial infarc- 
tion, antecedent angina pectoris, d.s_. ; hates mellitus, histcru I 
of never smoking and compromised hemodynamic status as 
expressed by systolic hypotension (blood pressure 
195 mm Hg) or higher Killip ciess hi wry. Systolic hypo- 
tension and Killip class > I incurred an independent three- to 
fourfold increase in mortality risk. The other five risk factors 
were associated with a I.2 to 2-fold increase in mortality 
rate. Persons who had never smoked had a higher mortality 
risk (odds ratio 1.4) than that of active or former smokers 
even after adjustment for other potentially confounding 
variables. No institutional characteristics affected mortality. 
Expected and observed morlrli(y rates by risk defile and by 
cuuntry (Tables 6 and 7). Table 6 shows the total patient 
group grouped by deciles according to increasing probability 
of dying because of increasingly unfavorable risk profiles 
and the expected and observed mortality in each decile. The 
diierences between the observed and expected 30-day mor- 
t&y rates in each decile were not significant, indicating a 
satisfactory goodness nffit to the multivariate logistic model. 
The 30-day mortality rate of the i,612 patients with the most 
unfavorable risk profiles (deciles 9 and IO) was 26.0%; that of 
the 1,606 patients with the lowest associated risk (defiles I 
and 2) was 1.2%. Belonging to the two highest risk deciles 
predicted the 30-day mortality with a sensitivity of 58.6% 
and a specificity of 83.7%. 
The expected and observed mortality rates of the differ- 
ent participating countries (except Eounlry 13, which was 
excluded because of the small number of cases) are pre- 
sented in Table 7. The overall difference between the ob- 
served and expected rates was significant (p < O.OOi). When 
countries 5 and 2 were both excluded from the analysis 
(becatlse of the small patient numbers, exclusion of country 
12, with the lowest mortality, did not affect the results), the 
overall difference between the observed and expected mor- 
tality rates wns nat sipnificnnt, whereas when only o%e of 
these two countries was excluded, the diiference remained 
significant. 
In an attempt to evaluate why the mortality rates were 
significantly lower than expected in country 2 and signifi- 
cantly higher than expected in country 5. the country- 
specific mortality odds ratios associated with each cf the 
seven risk baseline characteristics were calculated (Table 5). 
In b@th countries the odds ratio associated with Killip 
class 11 exceeded the odds ratio in the tatal study popula- 
tion, and the overall differences in these odds ratios were 
significant (p < O.OitOi j. Mthough country 5 dso had a higher 
predictive rate for diabetes mellitus than that of the total 
group, the difference was not significant. The odds ratios 
associated with all other baseline risk variables were statis- 
tically similar in all countries. 
DIscussion 
The purpose of this analysis was to describe and attempt 
to clarify the reasons for the considerable variability in the 
Country 5 1102&821t 
Odds ratio 
ConRdence limits 
co&y 1[65/1,oso]t 
Odds ratio 
Confidence limits 
1.98 1.85 5.79 1.30 2.11 099 1.2 
(1.54. 2.55) (0.59. 3.461 (3 49.9.611 (074.226, 11.31.4.08~ 10.59. 1.7)! [0.62,2.a) 
1.94 2.42 4.91 I 69 1.35 I.80 1.48 
(1.42. 2.66, 10.99.S.90~ 12.83. 8.53) 10.90. 3.17) ;074.2.461 fI.M. 3.31) f0.W. 2.721 
2. respectively. BP = blood prrsure. 
mortality rates among the patients enrolled in different 
countries that participated in the International Tissue Plas- 
minogen Activator Streptokinase Mortality Trial. Recruited 
paiients in all countries fulfilled identical inclusion and 
exclusion criteria and received similar thrombolytic and 
postthrombolytic management in each arm. To evaluate the 
role of differences among countries in the distribution of 
baseline risk factors, a multivariate analysis was performed 
identifying the factors that independently affected mortality 
in the total study group as well as in each country. The 
analysis of the total study group confirmed earlier observa- 
tions on the prognostic importance of older age. antecedent 
angina, previous infarction or diabetes mellitus (6,7) and 
compromised hemodynamic status on admission (8,9) in the 
prediction of mortality. The mortality odds ratios for com- 
promised hemodynamic status (Killip class > I) differed 
significantly among countries, whereas rhe odds ratios asso 
Tabk 6. Expected and Observed 3MJay MorLality Rates by 
Risk Decile 
Exaecled Observed 
Defile h&lily Monalily Palienrs 
afRisk 1%) 0%) NO.1 
I 0.9 0.9 BD3 
2 I.6 1.6 803 
3 2.4 1.9 8w 
4 3.3 3.2 805 
5 4.4 5.0 w 
6 5.8 5.2 Eu3 
7 7.7 8.3 805 
8 IO.7 10.7 F.04 
ovtrall 8.9 8.9 8.041’ 
*Excluding cowdry I3 bscausc cd a small sludy population and 307 
palicnls fan other countries wilh incomplete baeliee vtiabkr. 
ciated with all other prognostic risk factors were statistically 
similar. 
Beyond risk (srtors. The expected mortality figures based 
on the distribution of individual probabilities of dying ac- 
cording to risk factor protite within countries elfactively 
predicted the actual mortality in most countries. However, 
the considerable discrepancy between the observed and 
expected mortality in two countries testifies to the incom- 
pleteness of this model. The relatively low sensitivhy asso- 
ciated with the two upper decides of individual probability of 
dying within 30 days of admission also indicates tbat the 
seven risk variables cannot explain a considerable portion of 
the deaths. 
In country 5 the odds mtio associated with higher Fillip 
class significantly exceeded the respective odds ratio ob- 
served for the totat study group. However, this observation 
could not explain the higher mortality rate because country 
2. which also had a high odds ratio associated with Kitlip 
class 5 I, had a Iowa rate. 
Thus, it is plausible that additional inherent differences 
contribute to the diiercnces in mortality. Such differences 
could originate from diierences in medical management. 
However, the lack of association of mortality mtes with 
characteristics of the panicipating medical centers (size of 
center, university alEGation and presence of sophisticated 
cardiologic services) seems to preclude a prominent role for 
these factors. 
Another potential explanation for the diaererll motity 
rates could be differences in postthrombolytic treatment 
policies such as a more aggressive use of cardiac catheter- 
ization and angioplasty. Such an approach has been as- 
sociated with an increased in-hospital complication rate 
and even an increased mortality (10-12). However, our 
data indicate that use of postthrombolytic management 
was conservative in all participating countries with very 
low rates of revascuiarization procedures. Atso the poten- 
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Tublo 7. Expected and Observed Mortality Rates by Counny (n = W3P 
Country’ I 2 3 4 5 6 7 8 9 10 II 12 
Expected mortality (%) 7.8 a.2 10.6 10.3 9.0 9.8 8.1 10.1 9.2 7.1 8.2 4.9 
Obrcrved modality (%j 8.3 6.2 9.0 9.7 15.0 7.7 8.6 10.3 9.0 7.1 9.2 2.9 
Paticnts enro”cd mo., 1.506 l.OH) IM)l 983 682 543 513 486 457 380 337 105 
‘Ercluding wuntly 13 bccnuse of s&l study pop&ion and 307 pat&s from olhercaunti with incomplclc baseline variables. 
tial effect of different policies regarding length of stay 
after myocardial infarction on observed in-hospital mortality 
was negated by use of 30-day mortality as the outcome 
variable. 
Nevertheless. genetic and environmental factors may _ 
interact with other patient characteristics in determining the 
risk of myocardial infarction (13). Genetic factors may also 
influence the dynamic balance between thrombosis and 
endogenous tibrinolysis. Several studies have demonstrated 
racial differences in endogenous librinolytic activity (14-B) 
and indicated that some populations may be more sensitive 
to thrombolytic therapy (19). 
Our findings suggest that the recognized risk factors 
associated with increased mortality after acute myocardial 
infarction are insufficient to account for differences across 
populations, even when these populations are homogenous 
with respect to selection and treatment criteria. Other inves- 
tigators (20-23) have made similar findings in attempting to 
predict the incidence of coronary disease among different 
populations. We also found that within populations, baseline 
risk factors accounted only in part fm mortaiity diierences. 
Other factors not included in the analysis, such as quality of 
clinical management, lifestyle or genetic factors, may have 
contributed to our findings. 
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